Real-World Patient Outcomes on the Efficacy of Lanreotide Treatment for Neuroendocrine Tumors: The Influence of Body Mass Index, Body Surface Area, and Renal Function
This large real-world data cohort of NET patients treated with lanreotide found no association of BMI, BSA, or renal function with PFS. Dose individualization of lanreotide treatment based on the patient characteristics BMI, BSA, or renal function does not seem rational based on these findings. .
Authors
- Mirjam Crul (ORCID: https://orcid.org/0000-0002-4929-2388)
- Heinz‐Josef Klümpen (ORCID: https://orcid.org/0000-0002-7290-1823)
- Tim Schutte (ORCID: https://orcid.org/0000-0002-4096-0917)
- Ilse de Weert
Institutions
- The Netherlands Cancer Institute (NL)
- Amsterdam University Medical Centers (NL)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Neuroendocrinology
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1159/000548257
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Amsterdam University Medical Centers